Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Real-time Estimate Cboe BZX
Other stock markets
 10:07:47 2024-05-09 am EDT 		5-day change 1st Jan Change
24.13 USD +1.34% Intraday chart for Dianthus Therapeutics, Inc. +5.68% +128.94%
Apr. 11 Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc CI
Mar. 22 Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating MT

Evolution of the average Target Price on Dianthus Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dd7cbe075866f462141.smHYCYCl3_rfE4KT4S-hNGxyXDIXgImdp9boF3uy4DM.iwruTcj1laC9SvL8iEWXBFo1GVVc1fHO7ayteRPHjAPQCJlh0u2WqJ5H7Q~cc62e5840483410916e4dd188542f6ad

Analyst Recommendations on Dianthus Therapeutics, Inc.

Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating MT
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating MT
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target MT
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate MT
Raymond James Starts Dianthus Therapeutics at Outperform, $24 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
23.81 USD
Average target price
50.17 USD
Spread / Average Target
+110.70%
High Price Target
84 USD
Spread / Highest target
+252.79%
Low Price Target
33 USD
Spread / Lowest Target
+38.60%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dianthus Therapeutics, Inc.

Wedbush
Stifel Nicolaus
Jefferies & Co.
Raymond James

Ratings for Dianthus Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. Consensus Dianthus Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW